Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Innovation Pharmaceuticals Inc IPIX

Healthcare Biotechnology
Innovation Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the business of developing or licensing small molecule therapies. The Company’s lead drug candidate, Brilacidin, is in a class of compounds called defensin-mimetics, small compounds that mimic the structure and function of defensins, also known as host defense peptides. The Company’s efforts... see more

Recent & Breaking News (GREY:IPIX)

Innovation Pharmaceuticals Collaborating with Regional Biocontainment Lab on Grant Application to Research Brilacidin as a Pan-Coronavirus Therapeutic

GlobeNewswire June 11, 2020

Innovation Pharmaceuticals Receives Data from Public Health Research Institute Showing Brilacidin Inhibits SARS-CoV-2 (COVID-19) in a Human Cell Line

GlobeNewswire May 26, 2020

Innovation Pharmaceuticals' Brilacidin Reduces Viral Titer of SARS-CoV-2 (COVID-19) by 75 percent After Only 1 Hour of Preincubation in In Vitro Study at BSL-3 Facility; Demonstrates Potent and Rapid Virucidal Activity

GlobeNewswire May 19, 2020

Inhibitory Effect of Innovation Pharmaceuticals' Brilacidin on SARS-CoV-2 (COVID-19) in Primary Human Immune Cells to be Studied at Leading Public Health Research Institute

GlobeNewswire May 5, 2020

Innovation Pharmaceuticals Informed Next Phase of Brilacidin Coronavirus (COVID-19) Testing to Begin Week of May 4

GlobeNewswire April 27, 2020

Screening of 11,552 Compounds Identifies Innovation Pharmaceuticals' Brilacidin as One of the Most Promising Potential Inhibitors of the Novel Coronavirus COVID-19

GlobeNewswire April 20, 2020

Innovation Pharmaceuticals in Discussions to Advance Brilacidin into Human Trials Against COVID-19

GlobeNewswire April 6, 2020

Innovation Pharmaceuticals Receives Data Supporting Brilacidin's Direct Inhibition of SARS-CoV-2, the Novel Coronavirus Responsible for COVID-19

GlobeNewswire April 1, 2020

Innovation Pharmaceuticals Brilacidin to be Researched as Possible Novel Coronavirus (COVID-19) Vaccine; Brilacidin Now Being Tested as Drug and Vaccine at Different Institutions

GlobeNewswire March 17, 2020

Innovation Pharmaceuticals Announces Testing Procedures of Brilacidin Against Coronavirus (COVID-19)

GlobeNewswire March 12, 2020

U.S. Regional Biocontainment Lab to Begin Testing of Brilacidin Against Coronavirus (COVID-19) Next Week

GlobeNewswire March 10, 2020

Innovation Pharmaceuticals Brilacidin Received by U.S. Regional Biocontainment Laboratory; Testing Against Coronavirus (COVID-19)

GlobeNewswire March 9, 2020

Innovation Pharmaceuticals Signs Second MTA to Explore Brilacidin as Coronavirus COVID-19 Treatment

GlobeNewswire March 6, 2020

Innovation Pharmaceuticals Plans for Phase 2 Trial of New Treatment for Ulcerative Colitis

GlobeNewswire March 5, 2020

Innovation Pharmaceuticals Provides Scientific Rationale and Clinical Development Perspectives for Brilacidin as a Potential Novel Coronavirus COVID-19 Treatment

GlobeNewswire March 2, 2020

Innovation Pharmaceuticals to Ship Brilacidin to U.S. Regional Biocontainment Laboratory for Research Against Coronavirus COVID-19

GlobeNewswire February 27, 2020

Innovation Pharmaceuticals Submits Material Transfer Agreement to Study Lead Defensin Mimetic Brilacidin for Coronavirus  (COVID-19)

GlobeNewswire February 24, 2020

Innovation Pharmaceuticals Exploring Lead Defensin Mimetic Drug Candidate Brilacidin as Potential Novel Coronavirus Treatment

GlobeNewswire February 18, 2020

Innovation Pharmaceuticals Phase 1 Trial of Brilacidin for Ulcerative Colitis Meets Primary Endpoints; Positive Topline Results of Oral Brilacidin

GlobeNewswire February 13, 2020

Innovation Pharmaceuticals Further Engages Locust Walk to Lead Out-Licensing Negotiations for Rights to Phase 3-Ready Oral Mucositis Drug Candidate

GlobeNewswire January 29, 2020